Publications by authors named "L Giaccone"
Article Synopsis
- Allogeneic stem cell transplantation (allo-SCT) offers curative potential for multiple myeloma patients but is effective in only a minority, with some patients experiencing long-term survival after relapse thanks to a combination of antimyeloma drugs and donor T cells.
- A study evaluating 242 multiple myeloma patients who underwent allo-SCT revealed a median overall survival of 39.4 months and highlighted factors like older age and previous therapies that predict shorter survival outcomes.
- Among 118 relapsed patients, various treatments were employed, with a significant portion receiving multiple lines of salvage therapy, including chemotherapy and immunomodulating agents, demonstrating a diverse treatment approach post-relapse.
Background: Despite the adoption of pediatric-like chemotherapy protocols, the introduction of new immunotherapies and a better understanding of the oncogenic landscape, the outcome for adult patients with acute lymphoblastic leukemia (ALL) remain substantially dismal. The aim of the present study was to evaluate the outcome in terms of survival in a cohort of adult patients with ALL who received allogeneic hematopoietic stem cell transplantation (alloSCT) between 2013 and 2023.
Methods: This was a single-center observational retrospective study including all consecutive adult patients with ALL who received an alloSCT between April 2013 and April 2023 at the Stem Cell Transplant Center AOU Città della Salute e della Scienza of Torino.
Background: Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population.
Methods: This multicentre, single-arm, phase 2 trial was conducted in 20 Gruppo Italiano Trapianto Midollo Osseo (GITMO) centres in Italy.
Article Synopsis
- Researchers studied how a treatment called Azacitidine-donor lymphocyte infusion (AZA/DLI) works for patients who had a relapse of a serious blood disease after a transplant.
- They found that 41.4% of patients responded well to the treatment, and the time they stayed healthy varied, with some doing really well and others not as much.
- The results showed that certain gene levels (WT1) and disease risk factors affected how long patients lived after the treatment, helping doctors understand who might need extra help.
Novelty in total body irradiation (TBI) as part of pre-transplant conditioning regimens lacked until recently, despite the developments in the field of allogeneic stem cell transplants. Long-term toxicities have been one of the major concerns associated with TBI in this setting, although the impact of TBI is not so easy to discriminate from that of chemotherapy, especially in the adult population. More recently, lower-intensity TBI and different approaches to irradiation (namely, total marrow irradiation, TMI, and total marrow and lymphoid irradiation, TMLI) were implemented to keep the benefits of irradiation and limit potential harm.
View Article and Find Full Text PDF